INTERNATIONAL law firm Addleshaw Goddard has advised artificial intelligence cardiovascular disease specialist GEN inCode UK Limited on a £3m fundraise from Maven Capital Partners and Downing LLP.
GEN inCode, which specialises in genetic risk assessment and prediction of cardiovascular disease through advanced genomic technology, will use the investment as a springboard for its rapid expansion and growth across the Europe, the UK and the US.
GEN inCode, which has significant operations in Barcelona, combines genetic and clinical data to evaluate and predict the onset of cardiovascular disease, which often leads to strokes, heart attacks and heart failure.
Its aim is to educate patients about cardiovascular risk and to improve public health by using the predictive capability of its products with targeted therapies to determine lifestyle choice and improve patient outcomes.
The advice to GEN inCode was provided by Addleshaw Goddard’s corporate team based in Glasgow. The team has advised GEN inCode since it was formed in 2018, on the initial investment rounds and now this institutional foundation investment by Maven Capital Partners and Downing.
Anna Brown, corporate partner at Addleshaw Goddard, said:
“This investment is expected be the springboard for rapid growth and expansion in Europe, the UK and US. The company’s diagnostic products and predictive capability has the capability to truly transform the assessment, treatment and prevention of cardiovascular disease. It can provide key information to patients, doctors and healthcare professionals enabling the application of both targeted therapies and the ability to effect lifestyle and behavioural changes. We look forward to seeing how GEN inCode can make a real impact on patient outcomes.
“Cardiovascular disease is the number one cause of death and disability worldwide, but it can be prevented. Addleshaw Goddard is delighted to support GEN inCode with its successful fundraise.”
Matthew Walls, GEN inCode’s chairman and chief executive, said:
“We are delighted to complete the institutional round of funding and welcome Maven and Downing, our new institutional investors. The funding will prepare the company for accelerated growth and international scale and supports our regulatory and clinical pathway into the US market. Anna Brown and her team at Addleshaw Goddard have provided invaluable support and guidance to the Company in this strategic investment.”
